Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion is a clinical-stage TechBio company with a promising AI platform that harnesses the power of artificial intelligence to develop novel vaccine candidates for cancer and infectious diseases. In a collaboration with Duke University, Evaxion presented a personalized vaccine strategy utilizing their AI-Immunology platform to identify both tumor neoantigens and endogenous retroviral-derived antigens for glioblastoma. With a Buy rating and a $16.00 price target, the company shows potential for significant growth in the future. However, risks to the outlook include potential issues with partnerships, technology, clinical trials, regulatory approvals, commercialization, legal and intellectual property, competition, and dilution.

Bears say

Evaxion is undergoing a strategic pivot into autoimmune disease (AID) therapies, aiming to optimize their AI-Immunology platform and select 2-3 lead indications for launch in 2026. However, without specific indications disclosed, it is unclear how marketable these therapies will be and the potential impact on Evaxion's licensing strategy. This lack of clarity, coupled with the uncertainty of niche versus higher prevalence AID indications, leads to a negative outlook on the stock.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of Jun 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.